Literature DB >> 9359845

N-terminal stretch Arg2, Arg3, Arg4 and Arg5 of human lactoferrin is essential for binding to heparin, bacterial lipopolysaccharide, human lysozyme and DNA.

P H van Berkel1, M E Geerts, H A van Veen, M Mericskay, H A de Boer, J H Nuijens.   

Abstract

Human lactoferrin (hLF), a protein involved in host defence against infection and excessive inflammation, interacts with heparin, the lipid A moiety of bacterial lipopolysaccharide, human lysozyme (hLZ) and DNA. To determine which region of the molecule is important in these interactions, solid-phase ligand binding assays were performed with hLF from human milk (natural hLF) and N-terminally deleted hLF variants. Iron-saturated and natural hLF bound equally well to heparin, lipid A, hLZ and DNA. Natural hLF lacking the first two N-terminal amino acids (Gly1-Arg2) showed reactivities of one-half, two-thirds, one-third and one-third towards heparin, lipid A, hLZ and DNA respectively compared with N-terminally intact hLF. A lack of the first three residues (Gly1-Arg2-Arg3) decreased binding to the same ligands to one-eighth, one-quarter, one-twentieth and one-seventeenth respectively. No binding occurred with a mutant lacking the first five residues (Gly1-Arg2-Arg3-Arg4-Arg5). An anti-hLF monoclonal antibody (E11) that reacts to an N-lobe epitope including Arg5 completely blocked hLF-ligand interaction. These results show that the N-terminal stretch of four consecutive arginine residues, Arg2-Arg3-Arg4-Arg5, has a decisive role in the interaction of hLF with heparin, lipid A, hLZ and DNA. The role of limited N-terminal proteolysis of hLF in its anti-infective and anti-inflammatory properties is discussed.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9359845      PMCID: PMC1218898          DOI: 10.1042/bj3280145

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  35 in total

Review 1.  Structure and biological actions of lactoferrin.

Authors:  J H Nuijens; P H van Berkel; F L Schanbacher
Journal:  J Mammary Gland Biol Neoplasia       Date:  1996-07       Impact factor: 2.673

2.  Identification of the bactericidal domain of lactoferrin.

Authors:  W Bellamy; M Takase; K Yamauchi; H Wakabayashi; K Kawase; M Tomita
Journal:  Biochim Biophys Acta       Date:  1992-05-22

3.  Killing of gram-negative bacteria by lactoferrin and lysozyme.

Authors:  R T Ellison; T J Giehl
Journal:  J Clin Invest       Date:  1991-10       Impact factor: 14.808

4.  Inactivation of C-1 inhibitor by proteases: demonstration by a monoclonal antibody of a neodeterminant on inactivated, non-complexed C-1 inhibitor.

Authors:  J H Nuijens; C C Huijbregts; G M van Mierlo; C E Hack
Journal:  Immunology       Date:  1987-07       Impact factor: 7.397

5.  Lactoferrin interacts with deoxyribonucleic acid: a preferential reactivity with double-stranded DNA and dissociation of DNA-anti-DNA complexes.

Authors:  R M Bennett; J Davis
Journal:  J Lab Clin Med       Date:  1982-01

6.  Modulation of natural killer and lymphokine-activated killer cell cytotoxicity by lactoferrin.

Authors:  H Shau; A Kim; S H Golub
Journal:  J Leukoc Biol       Date:  1992-04       Impact factor: 4.962

7.  Structure of human lactoferrin: crystallographic structure analysis and refinement at 2.8 A resolution.

Authors:  B F Anderson; H M Baker; G E Norris; D W Rice; E N Baker
Journal:  J Mol Biol       Date:  1989-10-20       Impact factor: 5.469

8.  Genomic organization of the bovine alpha-S1 casein gene.

Authors:  D Koczan; G Hobom; H M Seyfert
Journal:  Nucleic Acids Res       Date:  1991-10-25       Impact factor: 16.971

9.  The opposing actions in vivo on murine myelopoiesis of purified preparations of lactoferrin and the colony stimulating factors.

Authors:  H E Broxmeyer; D E Williams; G Hangoc; S Cooper; P Gentile; R N Shen; P Ralph; S Gillis; D C Bicknell
Journal:  Blood Cells       Date:  1987

10.  Human lactotransferrin: amino acid sequence and structural comparisons with other transferrins.

Authors:  M H Metz-Boutigue; J Jollès; J Mazurier; F Schoentgen; D Legrand; G Spik; J Montreuil; P Jollès
Journal:  Eur J Biochem       Date:  1984-12-17
View more
  33 in total

1.  A study of recombinant human lactoferrin secreted in milk of transgenic mice.

Authors:  A V Sokolov; M O Pulina; A V Kristiyan; E T Zakharova; O L Runova; V B Vasil'ev; Y G Gurskii; M M Minashkin; A N Krasnov; S G Kadulin; T G Ermolkevich; I L Gol'dman; E R Sadchikova
Journal:  Dokl Biochem Biophys       Date:  2006 Nov-Dec       Impact factor: 0.788

2.  Lactoferrin conjugated with 40-kDa branched poly(ethylene glycol) has an improved circulating half-life.

Authors:  Yasuhiro Nojima; Yosuke Suzuki; Kazuhiro Yoshida; Fumiko Abe; Tuneo Shiga; Takashi Takeuchi; Akihiko Sugiyama; Hirohiko Shimizu; Atsushi Sato
Journal:  Pharm Res       Date:  2009-06-25       Impact factor: 4.200

3.  Lactoferrin regulates an axis involving CD11b and CD49d integrins and the chemokines MIP-1α and MCP-1 in GM-CSF-treated human primary eosinophils.

Authors:  Colleen S Curran; Paul J Bertics
Journal:  J Interferon Cytokine Res       Date:  2012-06-25       Impact factor: 2.607

4.  Human lactoferricin is partially folded in aqueous solution and is better stabilized in a membrane mimetic solvent.

Authors:  Howard N Hunter; A Ross Demcoe; Håvard Jenssen; Tore J Gutteberg; Hans J Vogel
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

5.  N-linked glycosylation at Asn3 and the positively charged residues within the amino-terminal domain of the c1 inhibitor are required for interaction of the C1 Inhibitor with Salmonella enterica serovar typhimurium lipopolysaccharide and lipid A.

Authors:  Dongxu Liu; Cort C Cramer; Jennifer Scafidi; Alvin E Davis
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

6.  A complex of lactoferrin with monophosphoryl lipid A is an efficient adjuvant of the humoral and cellular immune response in mice.

Authors:  Grzegorz Chodaczek; Michal Zimecki; Jolanta Lukasiewicz; Czesław Lugowski
Journal:  Med Microbiol Immunol       Date:  2006-07-13       Impact factor: 3.402

7.  Lipopolysaccharide (LPS)-binding synthetic peptides derived from serum amyloid P component neutralize LPS.

Authors:  C J de Haas; R van der Zee; B Benaissa-Trouw; K P van Kessel; J Verhoef; J A van Strijp
Journal:  Infect Immun       Date:  1999-06       Impact factor: 3.441

8.  A high-throughput method for the quantification of iron saturation in lactoferrin preparations.

Authors:  Grzegorz Majka; Klaudyna Śpiewak; Katarzyna Kurpiewska; Piotr Heczko; Grażyna Stochel; Magdalena Strus; Małgorzata Brindell
Journal:  Anal Bioanal Chem       Date:  2013-04-21       Impact factor: 4.142

9.  In vivo diffusion of lactoferrin in brain extracellular space is regulated by interactions with heparan sulfate.

Authors:  Robert G Thorne; Aparna Lakkaraju; Enrique Rodriguez-Boulan; Charles Nicholson
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-09       Impact factor: 11.205

10.  Safety and tolerability of the antimicrobial peptide human lactoferrin 1-11 (hLF1-11).

Authors:  Walter J F M van der Velden; Thijs M P van Iersel; Nicole M A Blijlevens; J Peter Donnelly
Journal:  BMC Med       Date:  2009-09-08       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.